Investor Presentaiton
Our business has significant opportunities
beyond external expectations
Strong Foundation
• R&D has delivered: 9 new
medicines, numerous
milestones
•
Commercial execution is
strong: Key Inline & New
Products continue to grow
Business momentum is
robust: Strong base business
& expanding New Product
Portfolio
2023-2030 BMY External vs Internal Revenue Drivers
Consensus Drivers Drivers of Internal Conviction
⚫ IRA
•
LOE Exposure
In-line and recently launched products with
significant commercial opportunities
• 12 rapidly advancing new medicines in or near
registrational development
R&D productivity and efficiency enhancements
Strong financial capacity for business development
Bristol Myers Squibb™
Not for Product Promotional Use
5
LOView entire presentation